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Abstract 
To date, no effective therapeutic treatments have been developed for hypopharyngeal squamous 
cell carcinoma (HPSCC), a disease that has a five-year survival rate of approximately 31% because 
of its late diagnosis and aggressive nature. Despite recent improvements in diagnostic methods, 
there are no effective measures to prevent or detect HPSCC in an early stage. The goal of the 
current study was to identify molecular biomarkers and networks that can facilitate the speedy 
identification of HPSCC patients who could benefit from individualized treatment. Isobaric tags for 
relative and absolute quantification (iTRAQ) labeling was employed with two-dimensional liquid 
chromatography-tandem mass spectrometry to identify quantitatively the differentially expressed 
proteins among three types of HPSCC disease stages. The iTRAQ results were evaluated by lit-
erature searches and western blot analysis. For example, FUBP1, one of 412 proteins with sig-
nificantly altered expression profiles, was confirmed to have elevated expression in fresh HPSCC 
tissues. Integrin-mediated cell matrix adhesion and actin filament-inducing cytoskeleton remod-
eling were the cellular events that were the most relevant to HPSCC tumorigenesis and the 
metastatic process. The construction of transcriptional regulation networks led to the identifica-
tion of key transcriptional regulators of tumor development and lymph node metastasis of HPSCC, 
including Sp1, c-Myc and p53. Additionally, our study indicated that the interactions among Sp1, 
c-Myc and p53 may play vital roles in the carcinogenesis and metastasis of HPSCC. 
Key words: Proteomics  analysis; Metastasis; Hypopharyngeal squamous cell carcinoma; Tran-
scription factor network; iTRAQ; Carcinogenesis. 
Introduction 
Hypopharyngeal squamous cell carcinoma 
(HPSCC) is a serious health problem that caused ap-
proximately 2,330 deaths in the United States in 
2012[1]. In the recent decades, advances in diagnosis 
and treatment, but these efforts have resulted in mar-
ginal increases in survival times for patients [2]. The 
clinical management of HPSCC, which has a more 
latent location and possibility of metastasis than other 
tumors in the head and neck region, has several chal-
lenges, such as early detection and tailored therapy 
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[3]. One of the most challenging problems facing ra-
diologists is that the rapid differentiation of primary 
tumors and metastasis to lymph nodes requires 
evaluation of morphology by advanced methods such 
as computed tomography [4]. 
 HPSCC, which has a five-year survival rate of 
approximately 31%, cannot be treated with satisfac-
tion because of its late diagnosis and aggressive na-
ture [5].  Early diagnosis  is hampered by asympto-
matic traits and limited diagnostic approaches; 
therefore, it is necessary to identify molecular bi-
omarkers that will enable the rapid identification of 
HPSCC patients who could benefit from personalized 
treatment [6]. Molecular biomarkers, such as p53, Rb, 
p16, PTEN and hTERT, have been reported as prog-
nostic indicators for several types of cancers, includ-
ing HPSCC. However, none of these markers can sin-
gly contribute to the clinical decision-making process 
because each belongs to signaling pathways of multi-
ple known or unknown proteins [7].  Traditional 
methods of investigating proteins, such as western 
blotting, limit the number of proteins that can be in-
vestigated simultaneously. In contrast, proteomics 
studies can yield information on hundreds or thou-
sands of proteins. Recent developments in cancer 
proteomics, as well as powerful bioinformatics tools 
that integrate information about various tumor sup-
pressors, oncogenes, and complex molecular path-
ways, have contributed to the comprehensive analysis 
of HPSCC initiation, tumorigenesis, and metastasis 
[8]. 
Isobaric tagging for relative and absolute protein 
quantification (iTRAQ) is a proteomics technique de-
veloped to quantitatively investigate protein abun-
dance changes in different biological samples with 
high accuracy and reproducibility [9]. In this study, 
we employed iTRAQ  combined with off-line 
two-dimensional (2D) LC-MS/MS to acquire 
mass-spectrometry results, which were converted into 
protein-identification results and collected to analyze 
the relative abundance changes of HPSCC-related 
proteins in tumor tissues by Protein Pilot  software. 
After validation of the iTRAQ results by literature 
mining and western blotting, Cytoscape and Meta-
Core programs were employed for bioinformatic 
analysis of functionally related proteins and to obtain 
a more comprehensive insight into the molecular 
mechanisms that potentially underlying metastasis 
and tumorigenesis in HPSCC. Additionally, we in-
vestigated transcription factor crosstalk and regula-
tory networks that are related with the processes in-
volved in HPSCC formation and development.  
Materials and Methods 
Sample Processing  
Ten paired fresh tissue samples, including pri-
mary cancerous tissues matched with adjacent 
non-cancerous tissues and metastatic lymph nodes, 
were collected randomly from patients who were di-
agnosed with HPSCC from February 2010 to No-
vember 2010 at the Department of Otolaryngology of 
Xiangya Hospital in Central South Universi-
ty(detailed clinical information see the table 1). Pa-
thology review confirmed the histological diagnosis 
of all patients. Three paired fresh samples for western 
blotting were collected in the same manner. Samples 
were cut into small pieces and frozen in liquid nitro-
gen or stored at -80°C until they were prepared for 
extraction. The Medical Research Ethics Committee of 
Xiangya Hospital (Changsha, China) approved the 
study. 
Protein Extraction and Digestion  
Clinical tissue samples were categorized into 
three groups: normal adjacent tissue (NAT, 5 mm 
from the margin of the tumor), tumor tissue (CA, 
primary tumor) and metastatic lymph node (LN). 
Briefly, each sample was pestled in liquid nitrogen 
and mixed with 250 μL lysis solution containing 0.5 M 
triethylammonium bicarbonate and 0.1% (w/v) SDS. 
The mixture was homogenized with probe sonication 
(30×0.1 s, power set to 150 W) prior to solubilization 
for 1 h at room temperature. Cell debris was removed 
by centrifugation at 12,000 rpm at 4 °C for 15 min. 
Finally, the total protein remaining in the supernatant 
material was quantified using the Bradford assay. 
Purification and digestion of the protein extracts 
were conducted as previously described  [10, 11]. 
Briefly, 100 mg of each extract was mixed with four 
volumes of cold (-20 °C) acetone containing 12% 
(w/v) trichloroacetic acid (TCA, Sinopharm Chemical 
Reagent Co., Ltd. Shanghai, China) and digested at 
37°C overnight using sequencing-grade modified 
trypsin (Sigma, St. Louis, MO, USA) at a pro-
tein-to-enzyme ratio of 20:1. 
Labeling with iTRAQ Reagents 
Using the iTRAQ kit (Applied Biosystems, Foster 
City, CA) protocol, the peptides were labeled with 
iTRAQ tags as follows: NAT, iTRAQ 118 (IT118); CA, 
iTRAQ 121 (IT121); LN, iTRAQ 119(IT119). The la-
beled samples were mixed and dried by a rotary 
vacuum concentrator (Christ RVC 2-25; Osterode am 
Harz, Germany).  Journal of Cancer 2014, Vol. 5 
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Peptide Fractionation and Off-Line 2D 
LC-MS/MS Analysis  
The pooled mixture of proteins extracted from 
patient tissue samples was fractionated using strong 
cation exchange (SCX) chromatography on a 20AD 
high-performance liquid chromatography (HPLC) 
system (Shimadzu, Kyoto, Japan). The sample was 
re-constituted with loading buffers A (10 mM 
KH2PO4 in 25% acetonitrile, pH 2.6) and B (10 mM 
KH2PO4 and 350 mM KCl in 25% acetonitrile, pH 2.6) 
and loaded onto a 2.1 x100 mm, 5 µm, 200 Å column 
(The Nest Group, Inc. MA) for separation  using a 
linear binary gradient of 0℃ 80% buffer B in buffer at 
a flow rate of 200 mL/min for one hour. 
The absorption wavelengths of the UV detector 
were set to 214 and 280 nm and a total of 25 SCX frac-
tions were collected along the gradient. The collected 
SCX fractions were dried using a rotary vacuum con-
centrator, dissolved in buffer C (5% ACN, 0.1% FA) 
and analyzed on a QSTAR XL system (Applied Bio-
systems) interfaced with a 20AD HPLC system (Shi-
madzu). Peptides were second dimension separated 
on a Zorbax  column (0.1 3 15 mm, 5 mm, 300 
Å;Microm, Auburn, CA). The HPLC gradient was 
5℃35% buffer D (95% ACN, 0.1% FA) in buffer C at a 
flow rate of 0.3 ml/min for 70 min. dissolved and an-
alyzed on a QSTAR XL system (Applied Biosystems, 
Carlsbad, CA, USA). In an information-dependent 
acquisition mode, an MS survey scan was acquired 
from m/z 400-1800 with up to the 4 most intense 
multiply charged ions selected for MS/MS analysis in 
the mass range m/z 100–2000. Each SCX fraction was 
analyzed in duplicate. 
Protein Identification  
Protein identification and quantification using 
the MS/MS spectra was performed using Protein Pilot 
v3.0 software (Applied Biosystems) according to the 
human International Protein Index (IPI) database 
v3.45. To minimize the false positive rate, a strict cut-
off for protein identification was based on the fol-
lowing criteria: unused ProtScore > 1.3 and more than 
one peptide with 95% confidence per repetition. Pro-
tein relative expression ratios were based on the peak 
area ratios of the peptides from the same protein. The 
resulting dataset was auto bias-corrected to eliminate 
any variability due to unequal mixing of the various 
labeled digests. Fold changes in protein expression 
greater than 1.2 or less than 0.8 were determined to 
indicate significant proteins. 
Western Blotting 
Western blotting was applied as described pre-
viously [12]. In brief, thirty microgram protein was 
loaded in 10% gels for sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS–PAGE) 
and transferred onto PVDF membranes (Millipore, 
Bedford, MA). A mouse poly-antibody against FUBP1 
(SC-101040, dilution 1:1000) (Santa Cruz, CA, USA) 
and a secondary antibody (Beyotime, China) were 
selected for incubation with the blotted membranes. 
An anti-β-actin antibody (Beyotime, China) was used 
as an internal reference. The experiments were re-
peated three times. 
Data Mining and Analysis  
MetaCore (Gene-Go; St. Joseph, MI, USA), an 
integrated program with manual databases and prac-
tical algorithms for functional analysis, was applied to 
the resulting dataset [13].  The enriched biological 
pathway was searched against Gene Ontology da-
tasets. To annotate the functions of the significantly 
expressed proteins that were identified in the study, 
the proteins were inputted into Gene-Go’s MetaCore 
for analysis. The significantly expressed proteins were 
converted into their corresponding encoding genes, 
which were used as the input list for the generation of 
regulatory networks using a Transcription Regulation 
algorithm. Next, thirty sub-networks that were cen-
tered on transcription factors were generated and 
ranked by a p-value and interpreted in terms of Gene 
Ontology. A TRANSCRIPTION FACTOR crosstalk 
map was derived from the FANTOM database 
(http://fantom.gsc.riken.jp) and visualized by Cyto-
scape software 2.6.2 [14]. 
To measure the reliability of the analysis results, 
comparisons with HPSCC genes published on Pub-
med (http://www.ncbi.nlm.nih.gov/) and in EBI 
datasets (http://www.ebi.ac.uk/) were  computed 
(up to June, 2013), and the Venny graphic tool 
(http://bioinfogp.cnb.csic.es/tools/venny/index.ht
ml) was used to describe the consistency within the 
above data. In addition, we converted our results into 
Microsoft Access data and randomly selected one of 
the datasets using a computer-generated algorithm. 
Next, western blotting was used to validate the se-
lected proteins. After log transformation based on 1.2, 
all the protein expression data were loaded in cen-
troid-linkage hierarchical clustering assay using 
Cluster3.0  (http://bonsai.hgc.jp/~mdehoon/ 
software/cluster/software.htm#ctv)[15].  Then  Java 
Treeview  software  (http://jtreeview.sourceforge. 
net/)  were performed to present  the hierarchical 
protein groups in the three types of samples. 
Cell culture and proliferation 
Tu686, M2 and M4 cell lines were primary tumor 
and different metastatic potential cell lines generated 
from lymph node as described previously[16], which 
were gifts from warm heartedness Dr. Zhuo (Georgia)  Journal of Cancer 2014, Vol. 5 
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Chen (Emory University Winship Cancer Institute, 
Atlanta, Georgia). Tumor Cell lines were maintained 
as monolayer cultures in Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 medium (1:1) supplemented 
with 10% fetal bovine serum (FBS) in a 37°C, 5% CO2 
humidified incubator. Medium was changed every 
other day. Exponentially growing cells were used for 
the following experiments.  
 Cell growth test is detected by cell count kit 8 
(Dojindo Molecular Technologies, Japan) at 450nm 
absorption like previously. In briefly, 1000 cells were 
seeding into 96-wells plate. The experiment was per-
formed in continuous six  days and repeated triple 
times. 
Results 
MS Results and Protein Abundance Changes in 
HPSCC 
Seventy-eight percent of the total proteins that 
were identified in the combined data sets overlapped 
between the two MS replicates, and 643 proteins were 
quantified using a calibration based on a 1% global 
false discovery rate. The abundance of 412 proteins 
was altered in CA vs. NAT, with 204 proteins being 
overexpressed (more than 1.2-fold), and 208 proteins 
being under-expressed (less than 0.8-fold), which we 
also considered to be significant proteins (Additional 
file 1: Table S1). Furthermore, we also determined that 
382 proteins showed differential expression in LN vs. 
NAT, 177 of which were overexpressed, and 205 were 
under-expressed (Additional file 2: Table S2).  
Evaluation of iTRAQ Results by Public Data 
Mining and Western Blotting  
To identify the reliability of the experimental 
results, significant protein names were mapped to 
previously  published literature and microarray ex-
pression datasets for primary human HPSCC sam-
ples. We subsequently used the Venny graphic tool to 
evaluate the number of biomarkers within our results 
and published data (Figure 1). As shown in Figure 1, 
386 candidates in our iTRAQ results were reported in 
the analyses of different types of cancer, 214 of which 
were reported in studies of HPSCC. The identification 
of proteins that are involved in cell proliferation, in-
vasion and migration from the iTRAQ dataset sug-
gests a role in HPSCC carcinogenesis and metastasis. 
For example, CDH1 (E-cadherin) expression de-
creased between normal mucosa, tumor, and meta-
static lymph node (CA/NAT  = 0.8166, LN/CA  = 
0.5546 and LN/NAT = 0.4571, respectively).  
In addition, we also verified the analysis results 
using a traditional approach. To investigate whether 
FUBP1 was overexpressed in HPSCC compared to 
normal tissue, we evaluated the protein’s expression 
in three fresh cancerous tissues and matched adjacent 
non-cancerous tissues by western blot analysis. As 
shown in Figure 2, the elevated expression of FUBP1 
was significantly different in tumor tissues than nor-
mal tissues. Given that FUBP1 was observed to over- 
expressed in several tumors [17], we further detect 
whether over-expressed FUBP1 in tumor cells would 
promote  cell growth. Comparing with  Tu686 and 
Vector control cells, the cell growth in elevated FUBP1 
significantly increased (p<0.05, Additional file 4: Fig-
ure S1).  
 
 
Figure 1: Venny diagram showed the distribution of proteins that exhibit the 
amount  of  probable biomarkers within  our results  and cancer-related  or 
HPSCC publications. 386 candidates in our iTRAQ results were reported to 
correlate to at least one of different types of cancer, 214 of which were re-
ported referring to HPSCC.* means only proteins presented in our iTRAQ 
results were searched. 
 
 
Figure 2: Western blotting showed the over-expression of FUBP1 protein in cancer tissue and cell rather than normal mucosa.  (A) 3 pairs of normal mucosa and 
tumor tissues respectively named NAT1/CA1, NAT2/CA2 and NAT3/CA3. β-actin was performed to be internal reference. (B) The expression of FUBP1in DOK, 
Tu686, M2 and M4 cell lines indicated FUBP1 up-regulated in malignant cell.  Journal of Cancer 2014, Vol. 5 
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Figure 3: Hierarchical clustering revealed that the global protein expressed 
tendency of from normal mucosa to tumor and metastatic lymph node. The 
color of green mean the relative abundance changed <0.8 whereas red color 
represented >1.2 and black color hold the value <1.2 and >0.8. The color from 
light to dark told the changed level from low to high. 
 
Cluster Analysis of Potential Biomarkers in 
HPSCC 
As shown in Figure 3, hierarchical clustering 
revealed that the differential expression trend of the 
significant proteins in NAT, CA and LN could sup-
port the different process of tumorigenesis and nodal 
metastasis. The global  proteins  clustering  in these 
processes may provide evidence indirectly supporting 
the hypothesis that the metastatic process was similar 
to both developments of secondary tumor from the 
primary site and tumor from normal mucosa.  
Gene Ontology Analysis of the Significant 
Proteins 
To annotate the dysregulated proteins in HPSCC 
further, we applied the MetaCore mapping tool to 
generate the enrichment analysis of pathway maps 
and cellular processes. Pathway analysis is used to 
provide comprehensive and novel insight into the 
potential biology that is influenced by differentially 
expressed proteins. Based the ability of pathway 
analysis to reduce complexity and increase explana-
tory power of the data[18],  clusters of under-  and 
overexpressed proteins were mapped into different 
pathways and cellular processes (Figure 4B and 4C, 
respectively). The Gene Ontology analysis indicated 
that the majority of enriched significant pathway 
maps were involved in keratin filament-mediated 
cytoskeleton remodeling and Cytoskeleton remodel-
ing-Regulation of actin cytoskeleton by Rho GTPases 
(Figure 5A and 5B, respectively).  
Transcription Factor Crosstalk and Regulatory 
Networks  
Differentially expressed proteins identified in 
the study were submitted to MetaCore and subjected 
to the Analyze Networks (AN) of the Transcription 
Regulation  and Transcriptional Factor algorithm to 
further investigate the unknown pathways and asso-
ciations between proteins. Thirty regulatory networks 
that were derived from the input lists in Additional 
file 1: Table S1 and Additional file 2: Table S2 of the 
supplemental materials were generated by this algo-
rithm. The top ten scored regulatory networks were 
ranked on p-values ranging from 2.44e-232 to 6.80e-102 
and were comprised of 48 - 105 proteins with altered 
expression (Additional file 3: Table S3), including the 
transcriptional regulation initiated by the activation of 
Sp1, c-myc, p53 and HNF4-alpha. These proteins were 
connected through interactions with proteases (e.g., 
MMP-2, caspase-7), receptors (e.g., EGFR, al-
pha6/beta4, integrin), enzymes (e.g., p300,  MDM2) 
and phosphatases (e.g., PPP2R2B) that were based on 
a MetaCore curated database. Therefore, any objects 
containing the most connections to the root objects 
(the transcription factors) could represent key regu-
lators in the clustered proteins. As shown in Figure 
6A, Sp1 could interact with many proteins in the as-
sociated network and directly or indirectly regulate 
their expression, including Profilin2, PCNA and 
HOXA7. P53 and c-Myc were also key network ob-
jects, and they are presented in Figure 6B and 6C (see 
Table 4 in the Supplemental Material for additional  Journal of Cancer 2014, Vol. 5 
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information). When all the networks were mapped to 
GO analysis, integrin-mediated cell matrix adhesion 
and actin filament-inducing cytoskeleton remodeling 
were the most relevant among the network processes 
(Figure 4C). A ranked set of pathways and processes, 
which contains proteins with differential abundance, 
could be beneficial to identify key drivers of HPSCC 
mechanisms of pathogenesis and metastasis. Fur-
thermore, the crosstalk between these key  network 
objects that involved all of the significantly altered 
proteins was based on the FANTOM database for a 
global perspective of these regulated networks (Fig-
ure  7). Interestingly, in accordance with MetaCore 
analysis, Sp1/c-myc and p53 were the most frequency 
targeted proteins in each of the interactions. Together 
with detailed transcription factor regulation maps, the 
transcription factor crosstalk map could describe the 
comprehensive molecular network involvement in the 
tumorigenesis and metastatic process of HPSCC. 
 
 
 
Figure 4: Top biological processes and maps of significant proteins in HPSCC. (A) The gene content is aligned between all uploaded experiments. The intersection 
set of the experiments is defined as “common” and marked as a blue/white striped bar. The unique genes for the experiments are marked as colored bars. The genes 
from the “similar” set are present in all but one (any) file. CA compared with NAT is marked as orange bars; LN compared with NAT is marked as blue bars. (B) 
Canonical pathway maps represent a set of about 650 signaling and metabolic maps covering human biology (signaling and metabolism) in a comprehensive way. All 
maps are drawn with GeneGo annotators and manually curated and edited. (C) These are about 110 cellular and molecular processes whose content is defined and 
annotated by GeneGo. Each process represents a preset network of protein interactions characteristic for the process. Experimental data is mapped on the pro-
cesses. 
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Figure 5: Experimental data from significant proteins is visualized on the maps of keratin filaments mediating-cytoskeleton remodeling (A) and Cytoskeleton re-
modeling_Regulation of actin cytoskeleton by Rho GTPases (B) as thermometer like figures. Upward thermometers have red color and indicate up regulated signals 
and down ward (blue) ones indicate down regulated expression levels of the genes. 
  Journal of Cancer 2014, Vol. 5 
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Figure 6: Transcriptional Factors Crosstalk and Regulation Networks in HPSCC. (A, B, C) Sp1, c-Myc, P53 (Homo sapiens), the top three) transcription regulation 
network were generated from active experiments. Thick cyan lines indicate the fragments of canonical pathways. Up-regulated genes are marked with red circles, and 
down-regulated ones with blue circles. The “checkerboard” color indicates mixed expression for the gene between files or between multiple tags for the same gene. 
 
Figure 7: The map of cross-talking within these transcriptional factors enriched in the current study.  Journal of Cancer 2014, Vol. 5 
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Discussion 
HPSCC is the poorest subtype of squamous car-
cinoma in the head and neck, which underlies a dis-
pute concerning whether different disease mecha-
nisms exist in subsites of head and neck cancers [19, 
20]. Compared to our previous work on laryngocar-
cinoma [11], the current investigation indicated that 
many comparisons can be drawn between hypopha-
ryngeal and laryngeal carcinoma (data not shown). In 
this study, we comprehensively analyzed the proteins 
with significantly different expression levels and with 
functions that were related to HPSCC initiation and 
metastasis. The iTRAQ results were verified by liter-
ature mining and western blotting. 
iTRAQ combined with 2D-LC/MS has been be-
come a useful and reliable technique in the explora-
tion of new and unknown mechanisms of complicated 
diseases  [21].  In our study, this advanced method 
generated regarding differentially expressed proteins 
that was used to generate hypothesis for further in-
vestigation. To validate the reliability of the technol-
ogy, the iTRAQ results were confirmed by literature 
review in Pubmed and western blotting. We deter-
mined that 71.6% of these proteins were correlated 
with other cancers, which indicated that our data 
were consistent with those of other scientists. Based 
on published literature  [17, 22, 23] and our iTRAQ 
results, FUBP1 was confirmed to be significantly 
overexpressed in tumor tissue compared to normal 
mucosa which keeps according with the literatures in 
liver and gastric  carcinoma. In addition, we found 
that elevated FUBP1 expression in Tu686 cells en-
hanced its proliferation. To our limited knowledge, it 
is first time to report FUBP1 as an oncogene in cell 
experiment. Taken together, our iTRAQ results pro-
vide adequate accuracy and precision in identifying 
differentially expressed genes that may serve as po-
tential targets for HPSCC.  
In the current study, hierarchical clustering was 
performed to investigate changes in protein expres-
sion among the three groups of samples. Tight clus-
tering between CA/NAT and LN/NAT revealed a 
similar change of these molecules in the process of 
HPSCC initiation and lymph node metastasis. Migra-
tion and invasion require the downregulation of cell 
adhesion molecules and cell cytoskeleton remodeling 
to facilitate cell motility. This model is in accordance 
with the Gene Ontology analysis results of the dif-
ferentially expressed protein list from the dataset.  
Transcription factors are viewed as key regula-
tors of cell fate and behavior [24]. Constructing net-
works that describe transcription factor crosstalk and 
regulation is necessary to elucidate the mechanisms 
that underlie the process of carcinogenesis and me-
tastasis. To the best of our knowledge, only a small 
number of studies have reported that transcription 
factor crosstalk is involved in HPSCC at the protein 
level. This study provides a new overall perception of 
the underlying molecular basis of HPSCC initiation 
and metastasis. We employed Panther/FANTOM 
Database and Analyze Networks (AN) and deter-
mined that the most important regulators of tran-
scription factor crosstalk were associated with key 
biological processes, such as keratin fila-
ments-mediated cytoskeleton remodeling and Cyto-
skeleton remodeling-Regulation of actin cytoskeleton 
by Rho GTPases. 
Specificity protein 1 (Sp1), a C2H2-type zinc 
finger protein, has been widely reported as a ubiqui-
tously expressed transcription factor that regulates 
various genes containing GC boxes within their pro-
moters  [25, 26].  In addition, accumulating evidence 
has demonstrated that frequent overexpression of Sp1 
exists in various types of human tumors including 
squamous cervical carcinoma, indicating that high 
Sp1 expression correlates with the aggressive biolog-
ical processes of these tumors [27-29]. To date, there 
has been limited research examining the role of Sp1 in 
HPSCC. In our current study, the core of the Sp1 
transcription regulation network was ranked as the 
most significant in the comparison of LN with NAT, 
which was consistent with cell-based experiments in 
head and neck squamous cancer [30]. Our previous 
studies indicated that epithelial mesenchymal transi-
tion (EMT) and anoikis-resistance are two character-
istics of metastatic HNSCC  cells [31].  Sp1 network 
molecules, such as PCNA, β-catenin, keratins, colla-
gens, fibronectin and vitronectin, are related to cyto-
skeleton remodeling and cell adhesion, and therefore 
participate in the regulation of the pathologic pro-
cesses of EMT and anoikis-resistance during lymph 
node metastasis. The detailed mechanism whereby 
Sp1 promotes malignant behavior in HPSCC requires 
further analysis.  
Wild-type p53 is considered a tumor suppressor 
gene, but mutant p53 can have an entirely opposite 
function, such as promoting tumor progression and 
metastasis [32]. Mutations in the p53 gene can be de-
tected in at least 50% of human cancer cells, including 
HPSCC [33]. Analysis of the entire coding sequence in 
21 primary HNSCC lines confirmed earlier studies 
that identified an increased incidence of p53 mutation 
is associated with the progression of HNSCC from a 
noninvasive to an invasive phenotype [34]. 
The current understanding of the function of p53 
was mostly derived from identification of genes with 
expression levels that are elevated by p53 activity, 
including p21 [35], BAX [36] and HnRNP-K [37]. A 
similar pattern is reflected in our current study.  Journal of Cancer 2014, Vol. 5 
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Ohlsson et al. reported that the interaction between 
p53 and Sp1 induced tyrosine phosphorylation in an 
osteosarcoma cell line via the regulation of insu-
lin-like growth factor-1 receptor expression [38]. 
Taken together with the crosstalk and regulation map 
of transcription factors, we determined that the in-
teraction of Sp1 with p53 may directly or indirectly 
affect the expression of extracellular matrix (ECM) 
components, for example, desmin, vimentin, kera-
tin14 and tropomyosin-1, that are related with cyto-
skeleton remodeling and cell adhesion and are critical 
EMT[39]. 
C-myc, which is deregulated in most human 
tumor types and stages, regulates cell cycle and cell 
growth, promotes genomic instability, and stimulates 
angiogenesis, cell transformation and apoptosis. In-
terestingly, cell cycle arresting genes, such as p15, p21 
and p27, and cell cycle promoting genes, including 
cdc25A, cdk4 and cyclin D2 [40], which are the tran-
scriptional targets of c-Myc, may account for cell 
transformation to a greater extent than c-Myc itself 
[41].  Furthermore, the central region of c-Myc can 
bind Sp1 transcription factor and inhibit Sp1 tran-
scriptional activity. This may be at least one of the 
mechanisms whereby c-Myc suppresses the tran-
scription of growth arrest genes [42]. Frederick et al. 
reported that the levels of c-Myc mRNA and protein 
were rapidly and profoundly decreased after infection 
with wild-type p53 in HNSCC cell lines [43], which 
supported the possibility that the reduction of c-myc 
may be attenuated by the accumulation of mutant p53 
in HNSCC patients. In addition, Joanna et al. deter-
mined that Sp1 could be a transcription cofactor that 
cooperates with p53 in the ablation of metabolic genes 
in diverse cancers, and p53 could inhibit c-Myc to 
mediate the ablation of several glycolytic genes in the 
human tumor cell line [44]. In this study, the interac-
tions among Sp1/p53/c-Myc could play vital roles in 
the process of HPSCC metastasis and carcinogenesis. 
In brief, we quantified differentially expressed 
proteins that are involved in HPSCC, and we devel-
oped transcription factor crosstalk and regulatory 
networks that are associated with the process of initi-
ation and metastasis via iTRAQ-2DLC-MS/MS and 
bioinformatic software analyses.  Hundreds of pro-
teins that are mapped onto such networks as the cy-
toskeleton remodeling and cell adhesion pathways 
were identified as molecules that have roles in tu-
morigenesis and metastasis.  
Clinical Perspectives 
The current study provides comprehensive  in-
sights into the molecular regulated and  interacted 
networks that are involved in HPSCC carcinogenesis 
and metastasis, which may help to identify new 
strategies to improve HPSCC survival. 
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